Member Info for Bensmith887

https://www.n4pharma.com/wp-content/uploads/2020/11/2020_SP_Angel_N4P_Initiation_Note_FINAL.pdf

• Novel vaccine delivery platform: N4 Pharma ('the Group', 'the Company', 'N4P') is focused
on the development of Nuvec®, a silica nanoparticle-based system for the delivery of
nucleic acid-based vaccines and therapies. The platform offers an alternative delivery
method to conventional systems. Potential benefits include an improved safety and
tolerability profile, a simple manufacturing process with rapid scale-up potential, and
biological stability. N4 Pharma has performed multiple in vivo and in vitro tests which
demonstrated that Nuvec® loaded with plasmid DNA (pDNA) and messenger RNA (mRNA).
can stimulate an immune response.
• COVID-19 project in the final stage: The COVID-19 pandemic has put the use of DNA/RNAbased vaccines into the spotlight. N4P is initiating a study to evaluate whether Nuvec®
loaded with DNA encoding a SARS-CoV-2 antigen can generate COVID-19-specific
antibodies in mice. Although N4P is not looking to develop a COVID-19 vaccine itself, the
successful completion of this project would demonstrate to potential partners the use of
Nuvec® as a delivery system and provide valuable data in a high-profile indication.
• Opportunities in other applications: The Group is expanding the potential applications
for Nuvec® outside traditional vaccine delivery to provide further market opportunities
for the system. The Group has identified potential for Nuvec® as an oral vaccine delivery
system and is undertaking initial proof-of-principle work in this area. Oral vaccination is a
novel administration route which could offer advantages over conventional injectionbased vaccine delivery. N4P also recently outlined a new programme to test the use of
Nuvec® for the delivery of gene silencing cancer therapies. Should the evaluation
programme be a success, it could unlock an additional commercial opportunity for the
Nuvec® platform.
• Optimisation work progressing: N4P continues to conduct studies to further understand
the activity of the Nuvec® platform and enhance its potential for nucleic acid delivery. The
Company has worked with Evotec and the Centre for Process Innovation to optimise the
molecule and is currently working with Nanomerics, a nanoparticle specialist. Nanomerics
is supporting a programme that aims to increase the reliability of the platform to generate
a consistent response in both in vivo and in vitro testing. An in vivo study using Nuvec®
generated from the optimisation programme is expected to commence in early 2021.
Outlook: N4 Pharma is well-positioned to offer developers an alternate delivery approach
for their DNA/RNA-based vaccine candidates. Supported by cash from a placing in May, N4P
is nearing completion of its COVID-19 programme. Positive results from this project would
be a significant milestone for the Group. Through the optimisation programme N4 Pharma
looks to progress Nuvec® to

Nuvec is a silva based nano particle..

In the article referenced here https://www.frontiersin.org/articles/10.3389/fimmu.2018.02224/full

‘The major advantages of inorganic NPs include low production cost, reproducibility and safety in application.’

Perfectly positioned for the current world problem at the moment!

Well worth a read, Nano particles are being used and working in clinical trials,..

This de risks the work n4p are doing somewhat.

https://www.dailymail.co.uk/health/article-8906965/Scientists-developed-COVID-19-vaccine-trigger-10-times-stronger-immune-response.htmlhttps://www.dailymail.co.uk/health/article-8906965/Scientists-developed-COVID-19-vaccine-trigger-10-times-stronger-immune-response.html

Worth a read if you want to know more about the technology!

https://res.mdpi.com/d_attachment/pharmaceutics/pharmaceutics-12-00294/article_deploy/pharmaceutics-12-00294.pdf

that would give us a £3bn market cap! as much as I would like that, 6 months seems unlikely!!

Create a new new account just to say that!?

Retesting the 20day moving average as we speak, hopefully a bounce from here!

I am an individual investor, and certainly not a professional Chartist, so with everything on here do you own research..

The key levels I am looking at however are...
13p- a daily inside bar formed after the big push up on the 10th August. If it clears that we could see another move.
18p- previous weekly resistance- and has the (number 8 in! !! :p )
21p - A big gap down in June 2018 which could be filled.

another person will find different levels I'm sure

Yes agreed it looks like a retest of 7.5p.
A weekly close above that 8p mark gives me some confidence on this one. ..

Its another perfect example of why you should always take some profit off the table when you get massive spikes like this... then you can enjoy the drop, rather than feel exposed ( like the people that were buying £50k+ at 14/15p!)

Hey all,
I had a quick look at the brands Traffic numbers in comparison to Boohoo,

Last 3 months traffic (sessions)
Boohoo- 9m -30% YOY
Simplybe- 3m - 15% YOY
Jd williams- 2.8m - 34% YOY
Jacamo- 900k - 44% YOY

Some other interesting take outs
- 33-46% of N brown's website traffic comes from Direct ( ie customer types JDwilliams into URL bar) suggesting a fairly high customer recognition/loyalty . this is 30% at Boohoo
- Boohoo Wins on Organic search vs N brown - which links into their younger demographic, who tend to use google search more and shop around0
- N brown look to be doing double the paid search activity as Boohoo, which will be because they cannot rely on organic search like boo hoo can.
- N brown brands have a much large gender and age profile than Boohoo. ( 70 % of Boohoo are women, 60% below the age off 44.) Giving a broader market scope/ less suitable to fashion change!?

If I was running N brown's websites I would drive organic search in a big way as they are losing in this space, I would also be watching my paid return on investment very closely, as overall market demand is down,so every customer that comes in needs to pay up!!

Re: Why invest.. From a technical perspective, the charts look bullish! but tight stop loos required!

Hi All, sharing my trade plan if you are interested.
https://invst.ly/rmv0w
Technical
1- Oversold on Weekly and monthly
2- At daily/ weekly resistance ( 50day MA & trend line)
3- Bull flag formed.
4- accumulation phase looks to be over.
Fundamental
1- Sales decline from covid is starting to decline
2- website traffic -20% YoY ( but improving, and below industry average)
3- 95% of their business is online.